MG
AGTC

Michael Gelband’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Michael Gelband’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-19,476
Closed -$59K – 2763
2021
Q3 		$59K Sell
19,476
-58,491
-75% -$208K ﹤0.01% 1961
2021
Q2 		$305K Buy
77,967
+55,205
+243% +$229K ﹤0.01% 1732
2021
Q1 		$115K Buy
+22,762
New +$118K ﹤0.01% 1963

Other funds holding AGTC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
AGA
Altrinsic Global Advisors Stamford, Connecticut $2.72B AUM 7.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Michael Gelband's AGTC Position: Q4 2021 in Review

Michael Gelband sold out of Applied Genetic Technologies Corporation (AGTC) in Q4 2021, closing a stake of 19,476 shares — an estimated $59K sold.

Michael Gelband first reported a position in AGTC in Q1 2021 and held it in 3 quarters. The position peaked at $305K in Q2 2021. 55 funds tracked by Wall St. Rank hold AGTC as of Q4 2021.

  • Michael Gelband reported no remaining Applied Genetic Technologies Corporation position as of Q4 2021 after selling out during the quarter.
  • Michael Gelband sold 19,476 Applied Genetic Technologies Corporation shares in Q4 2021, an estimated $59K.
  • Michael Gelband first reported a position in Applied Genetic Technologies Corporation in Q1 2021 and held it in 3 quarters.
  • Michael Gelband's Applied Genetic Technologies Corporation position peaked at $305K in Q2 2021.
  • 55 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.